Page 421«..1020..420421422423..430440..»

Modelling NZ’s Next Omicron Wave Expert Reaction | Scoop News – Scoop

Posted: June 4, 2022 at 1:46 am

How might waning immunity and reinfection affect our nextwave of COVID-19? Researchers have modelled differentscenarios to predict what the coming months might looklike.

The researchers found that a second COVID wavearose in the latter half of 2022 in all their scenarios,smaller than our first wave and set to peak in August toNovember depending on how fast immunity drops. However, ahigher peak of hospitalisations may occur if more olderpeople get infected. Under a faster-waning immunity scenariowith older ages more infected, this modelling estimates thatas many as 46% of cases could be reinfections.

The SMCasked experts to comment.

Dr Dianne Sika-Paotonu,Immunologist, Associate Dean (Pacific), Head of Universityof Otago Wellington Pacific Office, and Senior Lecturer,Pathology & Molecular Medicine, University of OtagoWellington, comments:

Waning immunity andreinfection

Many whove recovered from Covid-19will have developed immunity at least for the initial monthsfollowing infection, however reinfection risk with theSARS-CoV-2 virus remains. Although previous infection withthe virus does offer some immune protection, this does waneover time. More people have now been exposed to theSARS-CoV-2 virus, and with the emergence of the Omicronvariant, reinfections have been increasing in a way not seenwith earlier variants. Omicrons higher transmissibilityand ability to evade immune protection are likelycontributing factors.

Whats known from overseasstudies on reinfection risk

Towards the end of 2021as Omicron was spreading, data from South Africa was showinghigher reinfection rates when compared with previousinfection waves this pattern was also seen in othercountries. In the UK, the reinfection risk was found to be16 times greater when Omicron was the dominant variant,compared to when Delta dominated about seven months prior.This survey work was undertaken using random sampling ofhouseholds by the UK Office for NationalStatistics.

Data from England has also demonstrateda reinfection increase, where the rate of reinfections ofreported cases in February 2022 was about 10%, jumping fromjust 1% prior to mid-November 2021. One study from Qatar,which looked at the reinfection severity after initialinfection with the Alpha and Beta variants, indicated thatoverall, SARS-CoV-2 re-infections where anotherinfection occurred at least 90 days after the firstinfection tended to be less severe when compared withthe first infection.

Ongoing work will be needed tounderstand more about whether reinfections for Omicron andall its sub-variants are more or less severe, when comparedto the primary infection. It is still important that thosewho may have already had a Covid-19 infection furtherstrengthen their immunity withvaccination.

Overall, current evidence isindicating that reinfections have been increasing with theOmicron variant, and the risk of reinfection with theSARS-CoV-2 virus remains, especially for vulnerablecommunities.

Reinfection risk in NewZealand

Right now the daily reported COVID-19figures are still very high, and continue to place addedstrain and pressure on our health and other support systemsin Aotearoa New Zealand. The actual COVID-19 community casefigures are likely higher than those being reportedcurrently resulting from asymptomatic infection, and themajority of new community cases being detected by rapidantigen testing (RAT) with reliance on self-reporting ofresults. Reinfections in Aotearoa New Zealand will need tobe monitored carefully.

Impact of healthinequities

The COVID-19 pandemic has exacerbatedpre-existing inequities in health for vulnerablecommunities, and this includes for Mori and Pacificpeoples. It was known from the outset that Mori andPacific peoples were vulnerable to being disproportionatelyimpacted and affected by COVID-19 and therefore requiredprioritisation with respect to COVID-19 vaccination,prevention, and testing efforts. Inequities remain evidentwith vaccination and booster levels, and need to beaddressed with equity approaches that build trust and reducebarriers for people. Pacific peoples currently make up 11%of Covid-19 cases and more than double that 27% ofall hospitalisations.

Significant immunity gaps inAotearoa New Zealand exist right now as we move into winter.Children, tamariki and tamaiki aged 5-11 years still need tobe vaccinated against COVID-19 and many people are still toget COVID-19 boosters, with booster doses for the COVID-19vaccine now readily available for 16-17 year olds inAotearoa New Zealand.

Vaccination against otherillnesses

During the COVD-19 pandemic, there hasbeen limited exposure to other viruses such as the influenzavirus here in Aotearoa New Zealand, and there is potentialrisk of upcoming influenza outbreaks moving into winter. Wenow have more of the Influenza vaccines here being madeavailable for people these areimportant.

Lastly, although COVID-19 has been a keyfocus over the past two years, it is important to rememberthat all childhood vaccinations remain important. Regularchildhood vaccine schedules (non-COVID-19) for children,tamariki and tamaiki in Aotearoa New Zealand have beensignificantly affected by the Covid-19 pandemic. As aresult, there is potential risk of outbreaks for whoopingcough, measles and other illnesses that could be prevented.A resurgence of influenza and the respiratory syncytialvirus (RSV) could also possibly occur.

Noconflict of interestdeclared.

Scoop Media

Our aim is to promote accurate, evidence-based reporting on science and technology by helping the media work more closely with the scientific community.

The Science Media Centre is New Zealand's only trusted, independent source of information for the media on all issues related to science. Thousands of news stories providing context from and quoting New Zealand researchers have been published as a direct result of our work.

The rest is here:
Modelling NZ's Next Omicron Wave Expert Reaction | Scoop News - Scoop

Posted in Molecular Medicine | Comments Off on Modelling NZ’s Next Omicron Wave Expert Reaction | Scoop News – Scoop

Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia – GlobeNewswire

Posted: June 4, 2022 at 1:46 am

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced designation of AT-007 (gavorestat) as an orphan medicinal product by the European Medicines Agency (EMA) for treatment of Galactosemia (Galactosaemia).

We are pleased that the EMA has recognized the high unmet medical need in Galactosemia, the role of galactitol as the toxic metabolite responsible for long-term complications in Galactosemia, and the potential benefit of AT-007 treatment in reducing toxic galactitol levels, said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. Orphan designation for AT-007 marks an important step towards advancing our regulatory initiatives in Europe. We plan to meet with the EMA in the third quarter to discuss a potential MAA submission in Europe for conditional approval based on available biomarker data or for full approval based on expected clinical outcomes data.

Orphan medicinal product designation provides certain benefits and incentives in the EU, including protocol assistance, fee reductions, and ten years of market exclusivity once the medicine is on the market.

About Galactosemia

Galactosemia is a rare genetic metabolic disease resulting in an inability to metabolize the simple sugar galactose. Galactose is found in foods but is also produced endogenously by the body. When not metabolized properly, galactose is converted to the toxic metabolite, galactitol, which causes neurological complications, including deficiencies in speech, cognition, behavior, and motor skills, and also results in juvenile cataracts and ovarian insufficiency (in women). There are approximately 4,000 patients with Galactosemia in the EU and 120 new births per year.

About AT-007

AT-007 is a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in development for the treatment of several rare neurological diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. In clinical trials, AT-007 significantly reduced plasma galactitol levels vs. placebo in adults and children with Galactosemia. AT-007 is currently being studied in a Phase 3 clinical outcomes trial (ACTION-Galactosemia Kids) in children ages 2-17 with Galactosemia, as well as a long-term open-label study in adults with Galactosemia. In a pilot study, AT-007 significantly reduced blood sorbitol levels in adults with SORD Deficiency. AT-007 is currently being studied in a Phase 3 trial (INSPIRE) investigating biomarker efficacy, clinical outcomes, and significantly reduced blood sorbitol levels in adults with SORD Deficiency. AT-007 has received both Orphan Drug and Pediatric Rare Disease designations from the U.S. Food and Drug Administration (FDA) for the treatment of Galactosemia and PMM2-CDG, and Fast Track designation for Galactosemia.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Companys lead drug candidate, AT-007, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.

To learn more, please visit http://www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as may, will, expect, anticipate, plan, intend, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved.

Such risks and uncertainties include, without limitation, factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the Risk Factors contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Contacts

Investors:

Maghan Meyers(212) 600-1902 appliedtherapeutics@argotpartners.com

Media:

media@appliedtherapeutics.com

Applied Therapeutics, Inc.

View post:
Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia - GlobeNewswire

Posted in Molecular Medicine | Comments Off on Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia – GlobeNewswire

Study Empowers Long COVID Patients as They Struggle to Find Relief – Yale School of Medicine

Posted: June 4, 2022 at 1:46 am

Before coming down with COVID-19, Marjorie Roberts was known by friends and family as someone who always smiled.

On the morning of March 26, 2020, she was walking to her mailbox when she suddenly lost her balance and stumbled. At the moment, she didnt think much of it, but later that day, she describes feeling as though someone had [taken] a vacuum cleaner and sucked the life out of [her]. At 61 years old, she had never felt more sick in her lifeshe couldnt eat or sleep, suffered severe diarrhea and nightmares, and struggled to breathe. From that point on, she says, her life has not been the same.

Now, in 2022, her situation is only grimmer. She has developed spots on her liver, sarcoidosis in her lungs, and swollen lymph nodes. She also developed dry mouth so intense that it felt like someone was stuffing cotton in my mouth, as well as horrible bad breath. By the time she got to the dentist, seven teeth needed to come out. I always was the person who smiled, but now when I smile, the whole bottom of my mouth is gone, she says. Even if I wanted to take my mask off, I wont take it off, because COVID took my smile.

Pamela Bishop was a healthy, active, career-oriented professor at the University of Tennessee who had just launched her own research center before coming down with COVID-19 in December 2020. For the next three weeks, she says, she thought [she] was going to die every day. She suffered hallucinations, severe insomnia, and debilitating pain.

Bishop eventually recovered and returned to work in January 2021, but soon, she began having episodes of fatigue, brain fog, and nausea that forced her to lie down between meetings. The episodes increased in frequency until she realized she was horizontal more than she was up. I was sitting down to dinner with my husband [in March 2021] when I told him I didnt think I was getting better. I was damagedsomething was wrong with me, she says. This started the quest for figuring out what to do next.

Frank Ziegler used to go on long walks several times per week before January 14, 2021, when he thought he had developed a sinus infection. With a long history of these, he recognized the familiar pressure, stuffed ears, and drainage. But when he lost his sense of smell and received a positive result on his COVID-19 PCR test, he realized this wasnt a typical infection. Two months later, he began noticing hand tremors, cognitive issues, shortness of breath, and weight loss. Pre-COVID, I was very active and in good shape, he says. Now, just walking up the stairs puts me out of breath.

Millions of those who have recovered from COVID-19 are now experiencing a long string of often debilitating symptoms that persist weeks, months, or even two years or more following the original infection. As these long-haulers, most of whom are women, seek answers for their devastating and mysterious condition, many are also facing dismissal by their health care providers. Yale researchers Akiko Iwasaki, PhD, Sterling Professor of Immunobiology and Molecular, Cellular, Developmental Biology, professor of epidemiology (microbial diseases) and of dermatology, and investigator at the Howard Hughes Medical Institute (HHMI); and Harlan Krumholz, MD, Harold H. Hines, Jr. Professor of Medicine (Cardiology) and professor in the Institute for Social and Policy Studies, of investigative medicine, and of public health (health policy), are striving to solve the mysteries of long COVID, and to provide a compassionate voice for those feeling isolated and ignored by the medical community.

There are many people who have been infected with COVID who are suffering with an extraordinary set of symptoms, and yet, weve been unable to identify an approach which reflects their altered physiology, says Krumholz. However, their stories and experiences can help unlock what this is, and if we work together, we can make progress towards alleviating their suffering.

The Centers for Disease Control and Prevention (CDC) defines long COVID as having symptoms prolonging over four weeks after initial exposure to the virus, though according to Iwasaki, there is still no universal definition among scientists. The symptoms are highly variablelong-haulers have reported over 200 different symptoms. Common complaints include brain fog, shortness of breath, fatigue, difficulty concentrating, insomnia, tremors, gastrointestinal problems, palpitations, and both high and low blood pressure.

COVID-19 symptoms linger in approximately half to 75% of patients who suffered severe cases requiring hospitalization. But even among those who experienced mild or asymptomatic infections, many report developing persistent symptoms within the first two to three months after first being exposed. While there is not yet solid epidemiologic evidence on long COVID, Iwasaki estimates that between 10 and 30 percent of acute COVID-19 survivors develop the condition. Some people have mild cases of long COVID, but a significant number of people are disabled by this, says Iwasaki. Theyre suffering from financial difficulties because they cant work anymore, as well as the social and emotional impact of not being able to function in society.

One thing that is clear when I hear patients stories is that many people who were formerly extremely active and healthy have been relegated to a life where theyre able to do very little, says Krumholz. Someone just wrote to me today, saying that many of us [long-haulers] wish COVID had killed us because their lives have been so devastatingly affected.

Causes of long COVID are still unknown, but Iwasaki has several hypotheses. First, lingering viral remnants could be stimulating chronic inflammation. SARS-CoV-2 infection may also be triggering an autoimmune response within the body that leads to persistent symptoms. Long COVID could be the result of a latent virus like the Epstein-Barr virusthe pathogen that causes mononucleosisbecoming reactivated after COVID-19 infection. Tissue damage induced by infection that the body fails to repair properly could also be the culprit. These hypotheses, says Iwasaki, are not mutually exclusive, and many long-haulers may be suffering from a combination of these outcomes.

When Frank Ziegler began experiencing mysterious symptoms two months after coming down with COVID-19, he called his primary care provider (PCP). At the time, long COVID was just becoming a term, and he didnt yet know what it was. He wondered if he was the only person in the world to whom this was happening. My PCP basically patted me on my head and told me to go on my way, he says. I had only seen him for sinus infections through the yearshe knew Im not a hypochondriac.

Many long COVID patients, says Krumholz, are finding themselves in a similar position to Zieglers. There are no textbooks, no experts, no testing, and no treatments, says Krumholz. It makes it very difficult for patients, and they are often dismissed.

In her lab, Iwasaki is studying sex differences in the immune responses of people who develop long COVID. Of those who initially had a mild or asymptomatic infection that later developed into long COVID, she is finding, the majority are women between the ages of 20 and 60. Historically, medical conditions that predominantly impact women tend to be under-researched and ignored by the medical community, and this bias, she believes, may still affect attitudes when it comes to long COVID research and treatment.

It took a long time for medical researchers to recognize that this was a real disease, Iwasaki says. In the early days of the pandemic, womenas well as some menwere pretty much dismissed by their physicians, and some believed that it was all psychosomatic. And there are still physicians who believe this.

Marjorie Roberts and Pamela Bishop recall the frustration they felt when their health care providers wrote off their disabling symptoms as simply anxiety. My doctor told me that I was just mimicking what I saw on television, and that if I wanted to get better, I should watch Lifetime movies and do puzzles, says Roberts.

Bishop says she was also offered an antidepressant as the only option for treating the range of symptoms she was experiencing. When she later asked her provider for a referral to a specialist to treat her tinnitus, muscle cramps, fatigue, nausea, and other symptoms, she was again pushed to take the antidepressant. She was not offered any other options.

The fatigue you get from long COVID is not normal, and I knew this wasnt just anxiety, she says. She now attends a support group for long-haulers at Vanderbilt University, led by Vanderbilt professor and long Covid researcher James Jackson, PsyD, where 95 percent of the members are women. Bishop says many of the women also share similar stories of gaslighting or lack of awareness by medical professionals. When doctors tell you that nothing is wrong with you, you lose hope. Its dangerous.

Frank Ziegler first came across Krumholz after a friend had sent him an article from the Washington Post about long COVID. He was struck by the words of the Yale cardiologist, one of the doctors interviewed for the story, who called for providers to not dismiss the condition. I thought, 'there is a doctor that gets this! He understands, hes listening to his patients,' says Ziegler. Its a miracleI believe that. I dont believe in coincidences.

He decided to reach out via email on a Friday night, expressing his appreciation and sharing his own story. He didnt expect to get a reply, but to his surprise, Krumholz responded just two days later. Im not his patient, Im just someone from Nashville sending an email, says Ziegler. But he said he was really sorry for what I was going through, and he said that he would like to be able to talk to me more about this.

Ziegler told Krumholz about the Vanderbilt support group and expressed the groups desire to participate in research. Krumholz has teamed up with Iwasaki to launch the Yale LISTEN Study, or Listen to Immune, Symptom, and Treatment Experiences Now. More information can be found on Iwasaki and Krumholzs research on the Yale LISTEN study webpage.

The HHMI-funded project, part of the institutes broad support of COVID-related research at Yale, has two goals. First, its leaders plan to better understand the various patterns presented by long COVID by correlating specific biological signals with manifestations of the disease. They hope this will reveal underlying mechanisms that will help scientists develop appropriate, evidence-based therapeutics. Second, they hope the study will empower patients as they work together to find answers for their condition.

We want to do this study in a collaborative waythrough working in partnership with people and learning together, says Krumholz. We want to give patients agency over the data and enable them to make choices about the research they are a part of.

For many patients in the Vanderbilt support group, say Bishop and Ziegler, this is an exciting opportunity to take charge of their health. Many members of the group have been eager to enroll in medical studies, but finding a study to enroll in so far has been nearly impossible due to strict eligibility requirements of the limited number of trials available. Im looking forward to the LISTEN study. I am 100% on board, Bishop says. I have a lot to say, so a trial called LISTEN is perfect.

Indeed, both Iwasaki and Krumholz are dedicated to providing a compassionate ear to those in need. We see you, we recognize you, and we are doing everything we can to try and understand how this disease is mediated, says Iwasaki. We cant accept that this is going to be what it is and all these lives are going to unravel, says Krumholz. We have to do our best to move forward as teammates trying to push back the wave of ignorance and seeing if we can find things that work.

More:
Study Empowers Long COVID Patients as They Struggle to Find Relief - Yale School of Medicine

Posted in Molecular Medicine | Comments Off on Study Empowers Long COVID Patients as They Struggle to Find Relief – Yale School of Medicine

Researchers link sugar-studded protein to Alzheimer’s – ASBMB Today

Posted: June 4, 2022 at 1:46 am

In a bit of reverse engineering research using brain tissues from five people who died with Alzheimers disease, Johns Hopkins Medicine researchers say they discovered that a special sugar molecule could play a key role in the development of Alzheimers disease. If further research confirms the finding, the molecule, known as a glycan, could serve as a new target for early diagnostic tests, treatments and perhaps prevention of Alzheimers disease, say the researchers.

The study was published in theJournal of Biological Chemistry.

Alzheimers disease is the most common form of dementia in the United States. Affecting an estimated 5.8 million Americans, the progressive disorder occurs when nerve cells in the brain die due to the buildup of harmful forms of proteins called amyloid and tau.

Cleaning up the disease-causing forms of amyloid and tau is the job of the brains immune cells, called microglia. Earlier studies found that when cleanup is impaired, Alzheimers disease is more likely to occur. In some people, this is caused by an overabundance of a receptor on the microglia cells, called CD33.

Microglia cells function as macrophages in the central nervous system. They are the first immune cells to show up on the scene when something goes wrong in the brain and phagocytize various brain products, such as dying or dead cells.

Receptors are not active on their own. Something needs to connect with them to block microglia from cleaning up these toxic proteins in the brain, says Ronald Schnaar, Ph.D., the John Jacob Abel Professor of Pharmacology at the Johns Hopkins University School of Medicine and director of the laboratory that led the study.

Past studies by the researchers showed that for CD33, these connector molecules are special sugars. Known to scientists as glycans, these molecules are ferried around the cell by specialized proteins that help them find their appropriate receptors. The protein-glycan combination is called a glycoprotein.

In a bid to find out which specific glycoprotein connects with CD33, Schnaars research team obtained brain tissue from five people who died of Alzheimers disease and from five people who died from other causes from the Johns Hopkins Alzheimers Disease Research Center. Among the many thousands of glycoproteins they gathered from the brain tissues, only one connected to CD33.

To identify this mystery glycoprotein, the researchers first needed to separate it from the other brain glycoproteins. Since it was the only one in the brain that attached itself to CD33, they used this feature to catch it and separate it.

Glycans are made up of various sugar building blocks that influence the molecules interactions. Such sugars can be identified by their component parts. The researchers used chemical tools to deconstruct the glycan step by step, laying out the identity and order of its building blocks. The researchers identified the glycan portion of the glycoprotein as sialylated keratan sulfate.

Then, the researchers determined the protein components identity by taking its fingerprint using mass spectroscopy, which identifies protein building blocks. By comparing the molecular makeup of the protein with a database of known protein structures, the research team was able to conclude the protein portion of the glycoprotein was receptor tyrosine phosphatase (RPTP) zeta.

The researchers named the combined glycoprotein structure RPTP zeta S3L.

The group had previously found the same glycan signature on a protein that controls allergic responses in the airway, and that disrupting the glycan dampened allergic responses in mice.

We suspect the glycan signature carried on RPTP zeta may have a similar role in deactivating microglia through CD33, says Anabel Gonzalez-Gil Alvarenga, Ph.D., postdoctoral fellow in the Schnaar laboratory and first author of the study.

Further experiments showed that the brain tissue of the five people who died with Alzheimers disease had more than twice as much RPTP zeta S3L as the donors who did not have the disease. This implies that this glycoprotein may be connecting with more CD33 receptors than a healthy brain, limiting the brains ability to clean up harmful proteins.

Identifying this unique glycoprotein provides a step toward finding new drug targets and potentially early diagnostics for Alzheimers disease, says Gonzalez-Gil.

Next, the researchers plan to further study RPTP zeta S3Ls structure to determine how its attached glycans give the glycoprotein its unique ability to interact with CD33.

This article was republished with permission from Johns Hopkins Medicine. Read the original.

Go here to read the rest:
Researchers link sugar-studded protein to Alzheimer's - ASBMB Today

Posted in Molecular Medicine | Comments Off on Researchers link sugar-studded protein to Alzheimer’s – ASBMB Today

Barry named vice provost for graduate and professional education WSU Insider – WSU News

Posted: June 4, 2022 at 1:46 am

Psychology Professor and Graduate School Associate Dean Tammy Barry has been named vice provost for graduate and professional education at Washington State University. She will assume the new position, which was formerly titled Graduate School dean, effective July1.

Barry, who holds a doctorate in clinical psychology, also has served as the director of WSUs clinical psychology doctoral program. As associate dean, she oversaw the Graduate School function of program assessment and review, represented the Graduate School on the Committee on Institutional Accreditation and Program Assessment, and worked with the Provosts Office to meet the needs of institutional accreditation processes.

I am am thrilled to welcome Dr.Barry to the academic leadership team, and I know that she will bring a renewed energy to graduate and professional education across the WSUsystem, said Elizabeth Chilton, WSUprovost and executive vicepresident. Dr.Barrys commitment to collaboration and strong leadership was apparent throughout the interview process. It is clear that she has a firm understanding of graduate education at WSU and is well respected by the Graduate Schools staff and members of the University community.

In her new role, Barry will be charged with creating a vision for dynamic growth and excellence in WSUs graduate and professional education programs. This will include collaborating with academic leadership system-wide to conduct a careful assessment of WSUs current support for graduate and professional education. This assessment will include engagement with faculty and graduate student stakeholders, research into national best practices in the administration of graduate and professional education, and recommendations for changes to WSUs administrative and supportive services.

Barry earned her PhD from the University of Alabama. She completed her pre-doctoral clinical internship in the Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham School of Medicine, followed by an NIH-funded post-doctoral research position in the Department of Psychology at the University of Alabama. She was licensed as a psychologist in 2001. Before joining the faculty at WSU, Barry was an adjunct professor at the University of Alabama and interim director of its autism clinic. She has held positions as a visiting assistant professor at the University of Louisville, a tenure-track assistant professor at Texas A&M University, and a tenured associate professor at the University of Southern Mississippi, where she also served as the director of the clinical psychology doctoral program.

Barry is assuming the new role as Lisa Gloss, who holds a PhD in biochemistry, steps down as the Dean of the Graduate School and returns to her associate professor faculty position in the School of Molecular Biosciences. Gloss has served as the dean for more than three years and has been a committed leader of graduate education for WSU.

Here is the original post:
Barry named vice provost for graduate and professional education WSU Insider - WSU News

Posted in Molecular Medicine | Comments Off on Barry named vice provost for graduate and professional education WSU Insider – WSU News

Maine health care workers to appeal order to disclose their names in vaccine mandate lawsuit – Press Herald

Posted: June 4, 2022 at 1:45 am

Nine plaintiffs who anonymously sued Gov. Janet Mills over a COVID-19 mandate for health care workers will appeal a U.S. District Court judges decision requiring them to disclose their names by June 7.

The group filed its complaint in federal court last August, before the vaccine mandate for employees of designated Maine health care facilities went into effect Oct. 29.

Using pseudonyms, the health care workers argued that it was their religious right to refuse the vaccine overtheir belief that fetal stem cells from abortions were used to develop it. The state mandate does not allow for religious exemptions.

The Portland Press Herald, Kennebec Journal, Morning Sentinel and Sun Journal filed a motion in November challenging the groups right to file the complaint anonymously.

In his 13-page ruling Tuesday, Chief U.S. District Court Judge Jon D. Levy said he at first allowed the group to withhold their names because they argued they were afraid of the public passions concerning mandatory COVID-19 vaccinations, and that they were at a heightened risk of severe social stigma and worse if their identities were revealed.

In the final analysis, however, there is a near total absence of proof that their expressed fears are objectively reasonable, Levy wrote Tuesday. The Plaintiffs privacy interests have not been shown to outweigh the public interest associated with the presumption of openness that applies to civil proceedings.

Attorneys for the unnamed health care workers did not respond to requests Wednesday afternoon to discuss their appeal. They are represented by Maine attorney Steve Whiting, and lawyers from Liberty Counsel, a conservative, religious law firm based in Florida that has participated in several lawsuits against Maine and other states over COVID-19 vaccine mandates and restrictions. Nationally, the firm also has opposed safe and legal access to abortions and same-sex marriage, and the Southern Poverty Law Center has identified the firm as a hate group.

Before filing the notice to appeal, a spokesperson for Liberty Counsel told the Portland Press Herald on Tuesday night that the firm would not speak with reporters about Levys ruling because of the papers involvement in the lawsuit.

In an emailed statement Wednesday, attorney Sigmund Schutz, who represents the newspapers, said he plans to vigorously defend Levys order.

Chief Judge Levys decision vindicates the bedrock principle of the American justice system that courts operate in secret only in exceptional circumstances, Schutz wrote.

Shannon Jankowski, staff attorney for the Reporters Committee for Freedom of the Press, has joined Schutz as co-counsel. Jankowski said Wednesday that this is the only case the committee is involved in related to vaccine mandates, but that there are several court cases around the country in which people using pseudonyms have tried to challenge mandates. Jankowski said hundreds of other people around the country have filed complaints concerning vaccine mandates in their own names.

In Arizona in January, a judge denied a federal employees motion to anonymously sue President Biden over the U.S. governments vaccine mandate. At about the same time in Colorado, a judge agreed to let a group of university employees anonymously challenge their employers mandate.

These plaintiffs are attempting to invalidate a vaccine mandate that applies throughout the state of Maine, Jankowski said of the anonymous plaintiffs in the Maine lawsuit. This is something that has broad-ranging impacts on all citizens of Maine, and the public has the right to know who these plaintiffs are, what role they play in the health care system. Its important information for the public to be able to assess for themselves whats going on in this case.

Levy is still considering the lawsuit against the vaccine mandate. Meanwhile, federal judges have refused to block the mandate, which has been in effect since last Oct. 29. The states major health care providers reported at the time that most workers chose to get the shots and keep their jobs.

Invalid username/password.

Please check your email to confirm and complete your registration.

Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.

Previous

Next

See the article here:
Maine health care workers to appeal order to disclose their names in vaccine mandate lawsuit - Press Herald

Posted in Colorado Stem Cells | Comments Off on Maine health care workers to appeal order to disclose their names in vaccine mandate lawsuit – Press Herald

America’s return to the 19th century – York Dispatch

Posted: June 4, 2022 at 1:45 am

Lawrence Goldstone| The Fulcrum(TNS)

Pennsylvanians rally for women's rights in Harrisburg

Pennsylvanians rally for women's rights in Harrisburg

Daniella Heminghaus, York Dispatch

Ordinarily, the word unprecedented is hyperbole, similar to Breaking news! or Greatest ever! When used to describe the current danger to American democracy, however, it is all too appropriate. Never in the nations history have democratic institutions been so at risk under what would first appear to be banal circumstances.

There have been previous threats to Americas system of government, but each was spurred by a single overriding issue that created deep doubt as to whether democracy was up to resolving it. For the first 75 years of the nations existence, the United States wrestled with whether human slavery would be perpetuated or abolished, which left the Union teetering on the edge of dissolution. In 1861, it fell into Civil War, and the succeeding decades were spent trying to reinvigorate democracy, first by bringing Black Americans into the political system, then, in a sad irony, by shutting them out of it.

In the 1930s, during the Great Depression, with unemployment in excess of 20%, many Americans looked to Europe and what seemed to be the enormous success of Adolph Hitler and Benito Mussolini in pulling their countries out of similar quagmires and wondered if fascism might not be a better system for the United States. As Ira Katznelson described in his brilliant book, Fear Itself, it was only the political genius of Franklin Roosevelt that prevented fascism from gaining perhaps unstoppable momentum here.

More: Is democracy failing? Xi Jinping says it is, and he's not entirely wrong

More: White replacement theory is fascisms new name

More: Strengthening US democracy is critical to deterring future aggression

But slavery is no more although racism, sadly, persists and the economy, despite a job-crushing pandemic and high inflation, retains a solid base with unemployment matching a 20-year low. There is cause for dissatisfaction, surely, but if the past five years should have taught Americans anything, it is that the nations democratic institutions left it uniquely positioned to find solutions to even the most seemingly intractable problems.

It might appear odd, therefore, that a sizable segment of the American population seems willing, if not eager, to cast aside our most sacred traditions, not because of a threat from abroad or even, for all the chest thumping, one from within. At its core, these anti-democrats are using as their justification a claim to moral superiority, which overlaps with a desperate need to perpetuate minority rule.

The hypocrisy of those on this dubious high ground could not be more striking. Those who claim to be defending the lives of the unborn are all too willing to abandon those lives almost from the second they leave the womb. Those who claim to be defending liberty are content to see liberty be denied for their opponents. Those who scream about rigging elections and gaming the system spend a good deal of their time trying to rig elections and game the system. Those who decry cancel culture cheer the banning of books and restrictions on free expression in schools.

And, as the Supreme Court has repeatedly demonstrated in recent years, those who most vociferously defend religious liberty seek to impose their own religious beliefs on others.

In Masterpiece Bakeshop v. Colorado Civil Rights Commission, the court ruled that a vendor could refuse service to a gay couple on religious grounds. In a dissent on an emergency petition from Catholic health care workers in New York, Justice Neil Gorsuch favored granting them an exemption from the states vaccine mandate on the grounds that the vaccines had been developed from decades-old stem cells obtained from aborted fetuses. This despite directives from both the pope and the U.S. Conference of Catholic Bishops that taking the vaccine was both acceptable and advisable.

But it is in Justice Samuel Alitos leaked draft opinion in Dobbs v. Jackson Womens Health Organization that the full agenda of the Supreme Courts conservative majority became clear. Alito, in a 98-page opinion reeking with smug arrogance, belittled not only liberal justices who had defended a womans right to choose to have an abortion but also Republican appointees Harry Blackmun, David Souter, Sandra Day OConner and Anthony Kennedy for agreeing. He blithely tossed aside 50 years of precedent in Roe v. Wade and Planned Parenthood v. Casey as egregiously wrong from the day they were decided, self-righteously comparing his opinion to the overturn of Plessy v. Ferguson by Brown v. Board of Education. It seems to have eluded him that Plessy took away a right that Brown restored, which is precisely the opposite of what he and his four colleagues would do in Dobbs.

Abortion is one of the most delicate and difficult issues with which both the court and the country must grapple. As much as either side is loath to admit it, each has a point. Alitos opinion does not balance the nuances, however, but instead simply dismisses one side while fully embracing the other. His reasoning, as many legal analysts have pointed out, is contrived and transparently flawed religious dogma dressed up as law.

There is a word for a system of government in which the dictates of religion override other freedoms and civil guarantees. Theocracy.

One pundit said that with this decision and those on voting rights, the United States has officially returned to the 19th century. Others have described the decision as a triumph for originalism, and however questionable that legal philosophy may be, it is difficult to view it as anything but advocating a return to the 18th century. But Alito goes back farther than that. The root of conservative Catholic education remains the scholasticism of Peter Abelard, a 12th-century theologian who employed a similar version of Aristotelian logic in biblical analysis as does Alito in constitutional analysis. (This perhaps explains Alito using both 13th- and 17th-century sources as precedents.)

It would be one thing if Alito and his fellow conservatives were giving voice to the will of the people, which in theory is a precept of democracy. But instead, he is perpetrating the courts march to theocracy with both a religious and political minority. Catholics, of course, have the right to worship as they please and to follow the dictates of their Church, but Catholics are only 20% of the population. And with the exception of George W. Bushs victory over John Kerry in 2004, no Republican has won the popular vote for presid since George H. W. Bush in 1988.

While tyranny of the majority may put democracy at risk, tyranny of the minority is no democracy at all. Americans rejected slavery and Americans rejected fascism. The current threat is more subtle, thus more insidious, and so it remains to be seen whether Americans will reject theocracy as well.

Lawrence Goldstones most recent book is "On Account of Race: The Supreme Court, White Supremacy, and the Ravaging of African American Voting Rights."

The Fulcrum covers what's making democracy dysfunctional and efforts to fix our governing systems. Sign up for our newsletter atthefulcrum.us. The Fulcrum is a nonprofit, nonpartisan news platform covering efforts to fix our governing systems. It is a project of, but editorially independent from, Issue One.

View post:
America's return to the 19th century - York Dispatch

Posted in Colorado Stem Cells | Comments Off on America’s return to the 19th century – York Dispatch

Scientists Rejuvenate Skin Cells by 30 Years, with Pioneering Potential – BioSpace

Posted: May 15, 2022 at 2:54 am

As previously reported by BioSpace, a group of scientists from The Babraham Institutein the United Kingdom was able to successfully rejuvenate skin cells by a full 30 years.

The research team published a study in eLife Sciences last month describing their process of using induced pluripotent stem cell (iPSC) reprogramming to reverse aging effects at the cellular level.

Study co-author Ins Milagre told BioSpace that the research process was a team effort. In Lead Author Wolf Reiks lab, she was working on cell reprogramming while a colleague focused on the epigenetic clock.

Milagre came into her research career driven by an early interest in biology. I was fascinated by biology all of my life. I had a very good biology teacher when I was in high school, she said.

She explained that she was also a huge fan of the drama series The X-Files, seeing Gillian Anderson's character, Dana Scully, as a role model. I thought that being a scientist must be very cool. This combination made me decide to go into biology.

The research teams original hypothesis came from knowing that we can easily program cells to be zero years of age. No matter what age they are in the beginning, the cells normally reprogram back to embryonic age, or zero years of age.

Though reprogrammed embryonic cells are free of gradual aging decline, they lack identity and thus function. The research team began to consider what would happen if they could get the cells to only partially rejuvenate.

With embryonic cells, downstream applications can be a problem. We thought that maybe we could just rejuvenate the cells and then coax them back into being the cell of origin, Milagre explained. At first, the idea was casually discussed over happy hour, but then the team found that preliminary experiments yielded promising results.

They utilized Yamanaka factors (Oct4, Sox2, Klf4, c-Myc), which are typically used to differentiate cells into the embryonic stem cell stage. Instead of allowing the full time that it takes for cells to get to the embryonic life stage, we decided to stop the reprogramming process halfway through, Milagre said.

By doing this, we were able to get the cells to a younger age. They were easily reverted back to the original cell type, which in our case, were skin cells. Pausing the process in the middle allowed the cells to become a younger version of the same cell type. The researchers named the novel method maturation phase transient reprogramming (MPTR).

What I find very exciting about this study is that we showed that it's possible to rejuvenate cells, she said. Though the Yamanaka factors have been used in other labs, the Babraham Institute team was the first to rejuvenate cells by a full 30 years.

Courtesy ofFtima Santos

The scientists observed several benefits of the functionally younger cells. The skin cells were better able to produce collagen, and they were responding better to wound healing sites, Milagre said. The above photo depicts the collagen levels of the skin cells before and after rejuvenation. On the left are the original 53-year-old skin cells, and on the right are the reprogrammed cells. The collagen levels are depicted in red.

Milagre noted that the study is very preliminary, with much more research to be completed before the technology is safe and available. We only tested this in skin cells, so we don't know if this is also possible in other cell types, though we believe that it probably is based on similar work from other groups.

Another element that must be studied is how the technology will work without using the same viral vectors. We need to make a safer technology to do this. As a proof of principle, we showed that it's possible to rejuvenate cells by 30 years. Now, we need to do more research to be able to eventually move this technology into a more clinical setting.

Once the technology is safe and ready, Milagre noted that many downstream applications could be possible. We can think about trying to tackle neurodegenerative and degenerative disorders as well as ameliorating some aging effects. If we can get cells to be functionally younger, even if we don't expand peoples lives, we might be able to give people a better quality of life.

Reik explained in an earlier article that the findings could eventually lead to targeting specific genes that would be able to rejuvenate without any reprogramming. Milagre said that Yamanaka factors are working as pioneers that can start new gene expression programs. If we understand which genes are being activated downstream, we can eventually think about modulating these genes. We can try switching on a minimum number of effector genes. This would be a way to overcome using viral vectors.

Though potential future benefits of the findings are a long way off, the team is still considering the people they may help down the line. We hope the technology will help people live better lives without diseases, or without the consequences of a disease even if they still have it, Milagre said.

See more here:
Scientists Rejuvenate Skin Cells by 30 Years, with Pioneering Potential - BioSpace

Posted in Stem Cell Research | Comments Off on Scientists Rejuvenate Skin Cells by 30 Years, with Pioneering Potential – BioSpace

Insights on the Dimethyl Sulfoxide (DMSO) Global Market to 2027 – Expanding Research and Development in Stem Cell Transplantation to Benefit Demand…

Posted: May 15, 2022 at 2:54 am

DUBLIN--(BUSINESS WIRE)--The "Dimethyl Sulfoxide (DMSO) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Dimethyl Sulfoxide (DMSO) estimated at US$226.1 Million in the year 2020, is projected to reach a revised size of US$341.7 Million by 2027, growing at a CAGR of 6.1% over the analysis period 2020-2027.

Pharmaceuticals, one of the segments analyzed in the report, is projected to grow at a 6.6% CAGR to reach US$193.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Electronics segment is readjusted to a revised 5.8% CAGR for the next 7-year period. This segment currently accounts for a 22.9% share of the global Dimethyl Sulfoxide (DMSO) market.

The U.S. Accounts for Over 19.3% of Global Market Size in 2020, While China is Forecast to Grow at a 7.3% CAGR for the Period of 2020-2027

The Dimethyl Sulfoxide (DMSO) market in the U.S. is estimated at US$43.5 Million in the year 2020. The country currently accounts for a 19.25% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$152.5 Million in the year 2027 trailing a CAGR of 7.3% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.8% and 5.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR while Rest of European market (as defined in the study) will reach US$152.5 Million by the year 2027.

Chemicals Segment Corners a 15.9% Share in 2020

In the global Chemicals segment, USA, Canada, Japan, China and Europe will drive the 4.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$30 Million in the year 2020 will reach a projected size of US$41.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$29.9 Million by the year 2027.

Select Competitors (Total 42 Featured) -

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/pu434x

Go here to read the rest:
Insights on the Dimethyl Sulfoxide (DMSO) Global Market to 2027 - Expanding Research and Development in Stem Cell Transplantation to Benefit Demand...

Posted in Stem Cell Research | Comments Off on Insights on the Dimethyl Sulfoxide (DMSO) Global Market to 2027 – Expanding Research and Development in Stem Cell Transplantation to Benefit Demand…

Global Flow Cytometry Market is expected to grow at a lucrative rate of 8% to reach $11 billion by 2026 A Robust Tool that Defines New Era for…

Posted: May 15, 2022 at 2:54 am

Medi-Tech Insights

Increasing prevalence of HIV/AIDS and cancer, growing focus on immunology and immuno-oncology research, advent of AI platforms in flow cytometry workflows, increase in R&D investment to develop multicolor assays and advanced reagents are the key driving factors. However, high cost of flow cytometry products is still a major constraint for the Flow Cytometry market growth.

Brussels, Belgium, May 09, 2022 (GLOBE NEWSWIRE) --

Flow Cytometry is a technique used to detect and measure physical and chemical characteristics of a population of cells or particles usually suspended in a fluid using a laser beam. Most common types of flow cytometry-based proliferation assays are cell-based and bead-based assays.

Growing Adoption of Flow Cytometry in Stem Cell Research

Flow cytometry and cell sorting are critical tools in stem cell research. Recent advances in flow cytometric hardware, reagents, software platforms and algorithms have synergized to permit the stem cell biologist in better identifying and isolating rare cells based on their immunofluorescence and light scattering characteristics. By multiple fluorescent-labeled antibodies, researchers can obtain robust data and population-based statistics on differentiating stem cell cultures. The growing market penetration in stem cell research, adoption of recombinant DNA technology for antibody production, and evolution of tandem flow cytometry technologies is expected to open growth opportunities in the market.

Flow Cytometry is turning researchers into molecular detectives and helping them to delve into the depths of diseases. It allows researchers and scientists to probe the more complex and transient cellular changes that underpin the course of disease and responses to treatment, helping them better select the right drug target. - Senior Director, Data Sciences & Quantitative Biology, Pharmaceutical & Biotechnology Company, US

Rise in Chronic Diseases Increases Flow Cytometry Utilization

Story continues

Rising prevalence of chronic diseases such as cancer, hematological malignancies etc. is fueling the growth of the flow cytometry market. Flow cytometry is considered an efficient tool for clinical diagnosis of these diseases. Growing preference by health specialists to use allergenic and autologous stem cell therapies instead of radiation and chemotherapies is another key factor driving the flow cytometry market.

North America Leads in terms of Adoption of Flow Cytometry Market

North America dominates the global flow cytometry market with >40% share, followed by Europe. Growing research activities, well-established infrastructure and rising drug discovery development are the key driving factors.

Competitive Landscape: Flow Cytometry Market

The prominent players operating in the flow cytometry market are BD, Danaher Corporation, Luminex Corporation, Bio-Rad Laboratories, Apogee Flow Systems, among others.

Explore Detailed Insights on Global Flow Cytometry Market @ https://meditechinsights.com/flow-cytometry-market/

About Us:

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact Us:

Ruta HaldeAssociate, Medi-Tech Insights+32 498 86 80 79info@meditechinsights.com

See the rest here:
Global Flow Cytometry Market is expected to grow at a lucrative rate of 8% to reach $11 billion by 2026 A Robust Tool that Defines New Era for...

Posted in Stem Cell Research | Comments Off on Global Flow Cytometry Market is expected to grow at a lucrative rate of 8% to reach $11 billion by 2026 A Robust Tool that Defines New Era for…

Page 421«..1020..420421422423..430440..»